Squamous Cell Carcinoma News and Research RSS Feed - Squamous Cell Carcinoma News and Research

Squamous Cell Carcinoma is cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. Also called epidermoid carcinoma.
Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Increased use of SBRT linked to improved survival outcomes of NSCLC patients

Increased use of SBRT linked to improved survival outcomes of NSCLC patients

A new analysis of records in the Veteran's Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in recent years, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease. [More]
Added benefit of lung cancer drug not proven, says IQWiG

Added benefit of lung cancer drug not proven, says IQWiG

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. [More]
Computers could be more accurate than pathologists in assessing lung cancer tissues, study shows

Computers could be more accurate than pathologists in assessing lung cancer tissues, study shows

Computers can be trained to be more accurate than pathologists in assessing slides of lung cancer tissues, according to a new study by researchers at the Stanford University School of Medicine. [More]
Bio-Rad expands product line by launching two human recombinant antigens

Bio-Rad expands product line by launching two human recombinant antigens

Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced the launch of two human recombinant antigens, expanding the company's portfolio of Critical Raw Materials for the in vitro diagnostics market. [More]
TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). [More]
Scientists find link between makeup of individual's microbiome and head and neck cancer

Scientists find link between makeup of individual's microbiome and head and neck cancer

In a sample study, researchers at Johns Hopkins say they have found an association between the makeup of an individual's microbiome and head and neck cancer, a finding that potentially advances the quest for faster and more accurate cancer diagnosis and therapy. [More]
Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial. [More]
AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016. [More]
Loyola researchers detect tumor gene that may help predict survival outcomes in mouth cancer patients

Loyola researchers detect tumor gene that may help predict survival outcomes in mouth cancer patients

Loyola researchers have identified a tumor gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [More]
First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab. [More]
Molecular basis for tongue cancer progression: an interview with Dr Simona Principe

Molecular basis for tongue cancer progression: an interview with Dr Simona Principe

Head and neck cancers (HNC) are the sixth most common cancers worldwide, with approximately 600,000 new cases diagnosed every year. [More]
Combination drug therapy may stop KRAS-mediated lung adenocarcinoma

Combination drug therapy may stop KRAS-mediated lung adenocarcinoma

Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent. [More]
Diets high in glycemic index linked to increased risk of lung cancer

Diets high in glycemic index linked to increased risk of lung cancer

Consuming a diet with a high glycemic index, a classification of how rapidly carbohydrates elevate blood sugar levels, was independently associated with an increased risk of developing lung cancer in non-Hispanic whites, according to a new epidemiologic study from The University of Texas MD Anderson Cancer Center. [More]
P. gingivalis could be a novel risk factor for esophageal cancer

P. gingivalis could be a novel risk factor for esophageal cancer

University of Louisville School of Dentistry researchers have found a bacterial species responsible for gum disease, Porphyromonas gingivalis, is present in 61 percent of patients with esophageal squamous cell carcinoma (ESCC). [More]
New clinical trial launched to test potential drug that could help immune system combat cancer

New clinical trial launched to test potential drug that could help immune system combat cancer

Cancer Research UK's Centre for Drug Development, in partnership with Amgen Inc., has launched a new clinical trial to test a drug that could stop a patient's immune system from protecting tumours. [More]
Researchers examine molecular profile of HPV-positive oropharyngeal squamous cell carcinoma

Researchers examine molecular profile of HPV-positive oropharyngeal squamous cell carcinoma

Throat cancer patients exposed to both human papillomavirus (HPV) and tobacco smoke demonstrate a pattern of mutations along several key cancer genes, according to research presented today at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Advertisement
Advertisement